Azilsartan kamedoxomil
CAS: 863031-24-7
Ref. 3D-FA31501
1g | Discontinued | ||
2g | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued | ||
500mg | Discontinued |
Product Information
- 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester potassium salt
- 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl] -2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, potassium salt
- 1H-Benzimidazole-7-carboxylic acid, 1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1′-biphenyl]-4-yl]methyl]-2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, potassium salt (1:1)
- Azilsartan medoxomil monopotassium salt
Azilsartan is a drug used for the treatment of hypertension, diabetes, and other metabolic disorders. It has been shown to reduce chemoattractant protein levels that are associated with autoimmune diseases and renal cell cancer, as well as sodium citrate levels in bowel disease. Azilsartan medoxomil is a prodrug of azilsartan that is metabolized by esterases in the liver to form azilsartan. The analytical method used to detect azilsartan is an HPLC-MS/MS assay, which can also be used to detect the active metabolite medoxomil. Azilsartan should not be taken if there are any signs of liver impairment or kidney failure.